about
Discovery of small molecular inhibitors targeting HIV-1 gp120-CD4 interaction drived from BMS-378806.First discovery of novel 3-hydroxy-quinazoline-2,4(1H,3H)-diones as specific anti-vaccinia and adenovirus agents via 'privileged scaffold' refining approach.Novel diarylpyrimidines and diaryltriazines as potent HIV-1 NNRTIs with dramatically improved solubility: a patent evaluation of US20140378443A1.Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays.Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.Design, synthesis, and biological evaluation of novel 5-Alkyl-6-Adamantylmethylpyrimidin-4(3H)-ones as HIV-1 non-nucleoside reverse-transcriptase inhibitors.Design, Synthesis, and Biological Evaluation of Novel 2-(Pyridin-3-yloxy)acetamide Derivatives as Potential Anti-HIV-1 Agents.Synthesis and Biological Evaluation of a Series of 2-((1-substituted-1H-1,2,3-triazol-4-yl)methylthio)-6-(naphthalen-1-ylmethyl)pyrimidin-4(3H)-one As Potential HIV-1 Inhibitors.Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.Design, Synthesis, and Biological Evaluation of Novel 4-Aminopiperidinyl-linked 3,5-Disubstituted-1,2,6-thiadiazine-1,1-dione Derivatives as HIV-1 NNRTIs.Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.Novel diaryltriazines with a picolinonitrile moiety as potent HIV-1 RT inhibitors: a patent evaluation of WO2016059647(A2).Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket.Synthesis and Preliminary Antiviral Activities of Piperidine-substituted Purines against HIV and Influenza A/H1N1 Infections.Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs.Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain.Arylazolyl(azinyl)thioacetanilides: Part 19: Discovery of Novel Substituted Imidazo[4,5-b]pyridin-2-ylthioacetanilides as Potent HIV NNRTIs Via a Structure-based Bioisosterism ApproachOptimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant VariantExploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water SolubiliDesign, synthesis and biological evaluation of tacrine-1,2,3-triazole derivatives as potent cholinesterase inhibitorsMedicinal chemistry strategies of targeting HIV-1 capsid protein for antiviral treatment
P50
Q35244665-AEF4DC6A-1719-4F94-8F8F-9DEC5C8CEDC8Q36164152-B75F9616-630D-4B6A-A871-537EE89075B6Q38631098-767FCF72-607D-4691-8D41-EA6976903A7DQ38698714-83FBF5DE-C3C1-4441-A205-B643426C6AD1Q38740594-032FB0EC-38FD-4332-9BD4-58CC83AB6393Q38751051-2ECF528A-3D0B-498C-B8E4-9CB724C03F14Q38779515-09CB2087-432F-4C44-AB9C-AD1253571590Q38837121-82E17186-F911-4F0D-9A14-24EC8C158A12Q38915914-31C1BB22-8A60-4917-AB84-D2CF45B1A19AQ38915937-35B2FD3C-FB59-42AC-A18E-BC21AABED5A6Q38943621-12374E76-4F7D-4213-83E3-893EB8469C2EQ40211178-33F08C1E-CDB7-460C-ACB0-4377DAE2B46FQ40447961-5FCD449C-5A73-432B-B605-27CFF02C6C9DQ40630854-03F3BF04-512E-4A56-A617-ED6B53B4FDFEQ40820865-0B8EDC12-BA18-40A4-8C3C-D35F40F8E3E4Q40843871-1BF0EA0E-9B1D-4056-A334-D9B76A1D8281Q41534943-15C27330-558D-4F4E-9BA4-8C34674833DBQ42160586-63C6AB90-E04F-4E86-82A6-DCCD91C88900Q47620386-640FFD11-1B65-447C-87B1-4F4F1CB89975Q51718151-AA35AB7F-427C-481F-80FA-DD07E0DE7607Q52596192-9B594591-6F9D-4586-86CC-6F21600AA813Q52657521-ECDF5F23-6B77-4D1C-BD99-00605ED2E98AQ56786207-D028E23B-42CB-421A-8A55-D1A7C0F90BA6Q59357769-F7C28478-B517-46FC-8774-2A2ABDD2844EQ62141580-2B23FC82-F738-4EDD-A66C-A9D4FB3A986CQ90950457-33003257-A696-4533-9D88-93D7CF39A14BQ96132778-2B42AF24-663F-4989-9126-53FC89D41483
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Boshi Huang
@ast
Boshi Huang
@en
Boshi Huang
@es
Boshi Huang
@nl
type
label
Boshi Huang
@ast
Boshi Huang
@en
Boshi Huang
@es
Boshi Huang
@nl
prefLabel
Boshi Huang
@ast
Boshi Huang
@en
Boshi Huang
@es
Boshi Huang
@nl
P106
P1153
55877701100
P31
P496
0000-0003-2243-1947